Loading…
HUMALOG (KWIKPEN) is a brand name for Insulin Lispro, supplied as a solution. The medicine, its uses, side effects and dosage are the same regardless of brand.
Used for: AND CLINICAL USE .........................................................................3 CONTRAINDICATIONS .............................................................................................4 WARNINGS AND PRECAUTIONS.............................................................................5 ADVERSE…
Verbatim from this product's HC label. Tap a section to expand.
Serious Warnings and Precautions Hypoglycemia is the most common adverse effect associated with insulins, including the HUMALOG family of insulins. As with all insulins, the timing of hypoglycemia may differ among various insulin formulations.
Glucose monitoring is recommended for all patients with diabetes. Uncorrected hypoglycemic or hyperglycemic reactions can cause loss of consciousness, coma or even death (see OVERDOSAGE). Due to their quick onset of action, the HUMALOG (insulin lispro) family of insulins should be given within 15 minutes before a meal.
When necessary, HUMALOG (insulin lispro injection) may be given shortly after a meal instead (within 20 minutes of the start of the meal). HUMALOG 200 units/mL should not be administered via a subcutaneous infusion pump, or mixed with any other insulin (including HUMALOG 100 units/mL).
Insulin lispro solution in the HUMALOG 200 units/mL KwikPen cannot be transferred from the prefilled pen to other devices, such as a syringe. The markings on the insulin syringe will not measure the dose correctly. Overdose can result causing severe hypoglycemia.
When used via a subcutaneous insulin infusion pump, HUMALOG (insulin lispro injection) 100 units/mL should not be diluted or mixed with any other insulin. Patients should carefully read and follow the insulin infusion pump manufacturer's instructions and Part III- Consumer Information before use.
Any change of insulin or human insulin analogue should be made cautiously and only under medical supervision. ), species (beef, pork, beef-pork, human), and/or method of manufacture (recombinant DNA versus animal source insulin) may result in the need for a change in dosage (see DOSAGE AND ADMINISTRATION).
HUMALOG shall not be used if it is not water clear and colourless or if it has formed a deposit of solid particles on the wall of the vial or cartridge. HUMALOG MIX25 (25% insulin lispro injection, 75% insulin lispro protamine suspension) and HUMALOG MIX50 (50% insulin lispro injection, 50% insulin lispro protamine suspension) are white suspensions.
They should be administered by subcutaneous injection only and must not be administered intravenously. General As with all insulin therapies, the duration of action of HUMALOG may vary in different individuals or in the same individual according to dose, injection site, blood flow, temperature and level of physical activity.
Not medical advice. Always read the patient information leaflet and follow your prescriber or pharmacist.
Other brands of Insulin Lispro in Canada.
Know a brand we are missing in Canada? Suggest a brand →
Brand names are compiled from public regulatory records for active-ingredient mapping only. Drugvu is not affiliated with any manufacturer. This is not medical advice.
Hypokalemia is among the potential clinical adverse effect associated with the use of all insulin therapies, including HUMALOG. g. diarrhea). HUMALOG, HUMALOG 200 units/mL KwikPen, HUMALOG MIX25, HUMALOG MIX50 Page 6 of 63 Stress or concomitant illness, especially infectious and febrile conditions may change insulin requirements.
In these instances, patients should contact their physician and carefully control their blood glucose. To avoid transmission of disease, a cartridge or prefilled syringe should not be used by more than one person. HUMALOG (insulin lispro injection) had a similar safety profile to HUMULIN R (insulin injection (rDNA origin) Regular) over the course of the clinical studies.
HUMALOG has been shown to control glycosylated hemoglobin (HbA1c) levels as effectively as human insulin in comparator studies specifically designed to study meal time therapy without optimization of basal insulin regimens. Once a patient is using HUMALOG, reassessment and adjustment, as necessary, of the basal insulin regimen (dosage and number of injections) has been shown to optimize overall glycemic control.
Any fast-acting insulin formulation should be used with caution in patients with gastroparesis. However, some patients with gastroparesis may benefit from postprandial administration of HUMALOG, which has been shown to provide postprandial glycemic control similar to that provided by human insulin injected 30 minutes pre-prandially.
Using the postprandial dosing approach, the insulin dose can be adjusted according to the actual caloric intake and/or the observed rise in blood glucose following a meal.
Insulin plus Thiazolidinediones (TZDs):
TZDs, alone or in combination with other antidiabetic agents (including insulin), can cause heart failure and edema. The combination of insulin with a TZD is not indicated for the treatment of type 2 diabetes mellitus. Please refer to the respective TZD Product Monograph Warnings and Precautions information when the use of these drugs in combination with any insulin, including HUMALOG, HUMALOG MIX25 and HUMALOG MIX50, is contemplated.
Changes in Insulin Regimen/Transferring Patients from Other Insulins:
Patients taking a HUMALOG insulin may require a change in dosage from that used with their usual insulins. If an adjustment is needed, it may occur with the first dose or during the first several weeks or months. When patients are transferred between different types of insulin products, including animal insulins, the early warning symptoms of hypoglycemia may change or become less pronounced than those experienced with their previous insulin.
Transferring a patient to a new type or brand of insulin should be done only under strict medical supervision. , regular, NPH, or insulin analogs), or method of manufacture (recombinant DNA versus animal source insulin) may affect glycemic control and predispose to hypoglycemia or hyperglycemia.
Make any changes to a patient's insulin regimen under close medical supervision with increased frequency of glucose monitoring. Changes in insulin dose or an adjustment in concomitant oral antidiabetic treatment may be needed. If an adjustment is needed, it may be done with the first doses or during the first few weeks or months […]